Randomised Controlled Trial To Determine Efficacy And Safety Of Prescribed Water Intake To Prevent The Progression Of Autosomal Dominant Polycystic Kidney Disease (PREVENT-ADPKD)
Funder
National Health and Medical Research Council
Funding Amount
$746,751.00
Summary
Increasing the daily intake of water is well known to reduce the risk of developing kidney stones but there is growing evidence that it may also benefit other kidney diseases, particularly autosomal dominant polycystic kidney disease (ADPKD). This study will determine if adequate hydration can slow the progression of ADPKD, and could provide a relatively simple and cheap treatment for preventing the onset of kidney failure due to this disease.
Chronic Kidney Disease: Natural History Of Disease, Cost And Quality Of Life
Funder
National Health and Medical Research Council
Funding Amount
$72,281.00
Summary
Chronic kidney disease (CKD) is present in 12% of Australians aged over 25. CKD is associated with poor health outcomes including cardiovascular disease and progression to End Stage Kidney Disease. Many questions about CKD remain. My research aims to increase our understanding of the natural history of CKD in the Australian population, with focus on outcomes of CKD progression, cardiovascular and all-cause mortality, quality of life, and costs to society.
Periodontal Disease And Chronic Kidney Disease Among Aboriginal Adults; An RCT
Funder
National Health and Medical Research Council
Funding Amount
$1,035,550.00
Summary
Chronic Kidney Disease is a growing public health concern in Australia, especially among Aboriginal populations. It is associated with progression to end stage kidney disease requiring dialysis, cardiovascular disease burden and high mortality. This study will use a randomised controlled trial design to determine if comprehensive periodontal therapy reduces progression of kidney disease among Aboriginal adults with chronic kidney disease residing in Central Australia.
CKD-FIX: A Randomised, Controlled Trial Of Allopurinol In The Slowing Of Kidney Disease Progression
Funder
National Health and Medical Research Council
Funding Amount
$1,917,147.00
Summary
Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.
Centre Of Research Excellence: Partnering With Patients With Chronic Kidney Disease To Transform Care And Outcomes (CRE-PACT)
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
CRE-PACT will partner with patients to generate and translate new high-priority evidence to improve outcomes that are important to people living with chronic kidney disease (CKD). We will address the topics and questions most important to patients. We will build the next generation of research leaders and a community of research-ready patient-partners. There will be an integrated pathway for evidence translation and implementation at a global scale to improve patient-centred outcomes.
BRAIN-MEND: Biological Resource Analysis To Identify New Mechanisms And Phenotypes In Neurodegenerative Diseases
Funder
National Health and Medical Research Council
Funding Amount
$861,866.00
Summary
Current classification of neurodegenerative diseases (ND) based on clinical phenotypes does not take into account underlying disease heterogeneity, or overlapping disease mechanisms, thus hindering therapy development. Segregation and re-classification of ND phenotypes is urgently needed. BRAIN-MEND will reclassify existing phenotypic classifications using using pathway and network analyses within and across complex NDs.
Nodal Function In Peripheral Neuroinflammatory Disorders: Target Antigens, Functional Significance And Treatment Response
Funder
National Health and Medical Research Council
Funding Amount
$605,172.00
Summary
Inflammatory neuropathies are autoimmune disorders which produce severe disability and represent a costly burden to the healthcare system, but the causes remain unknown. Recent evidence from our team suggests that antibodies against parts of the peripheral nerve at the node of Ranvier are involved. The project aims to identify these specific targets and monitor treatment responsiveness, stabilise nerve function and prevent persistent disability.
Optimising Large-scale Public Health Interventions To Control Neglected Tropical Diseases
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Neglected tropical diseases (NTD) are a group of health conditions that affect the poorest of the poor, particularly in remote and rural areas. They affect the most vulnerable communities and cause substantial, chronic health harms impairing personal and social development. Several debilitating NTD are common in remote indigenous communities and Pacific islands. I propose a series of studies to investigate new strategies to control NTD in large populations where these diseases are endemic.
Optimising Heart Disease Prevention And Management
Funder
National Health and Medical Research Council
Funding Amount
$4,647,175.00
Summary
As we become older and risk factors such as obesity become more common, our biggest contributor to death and disability, cardiovascular disease (including heart disease), will continue to exert an enormous burden on our health care system and society. We will extend our ground-breaking research on multidisciplinary teams to create new and innovative health care programs to optimise the prevention and management of new heart disease and chronic forms of heart disease.
The Role Of Capsid Protein Nucleolar Localisation In Chikungunya Virus: Implications For Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$520,520.00
Summary
Chikungunya virus (CHIKV) is a globally widespread mosquito-borne alphavirus capable of causing considerable human morbidity and mortality. With no CHIKV vaccine or antiviral available this proposal aims to develop a live attenuated CHIKV vaccine, rationally designed by investigating the host cell nucleolar trafficking of CHIKV capsid protein. This vaccine has the potential to provide cross-protection against additional arthritogenic alphaviruses endemic to Australia such as Ross River virus.